Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Vila Nova De Gaia – page 6

150 clinical trials in Vila Nova De Gaia, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Vila Nova De Gaia at a glance
150
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

150 trials in Vila Nova De Gaia

Open in trial search

Safety and Efficacy of Intravesical Clostridium botulinum Neurotoxin Type A (150 kD) for Idiopathic Overactive Bladder in Women

Not yet recruiting
Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Vensica Medical Ltd.

Interstitial lung disease+1

Not yet recruiting

A Phase 2 Study Evaluating the Safety and Efficacy of Oral NS-863 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:Ns Pharma Inc.

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Urinary tract infection

Not yet recruiting

MV140 for Women with Recurrent Uncomplicated Urinary Tract Infections

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Inmunotek S.L.

Type 2 diabetes mellitus

Not yet recruiting

A study to evaluate the effectiveness of NNC0662-0419 and semaglutide in people with type 2 diabetes

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Idiopathic pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

K-ras gene mutation+2

Not yet recruiting

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Systemic lupus erythematosus

Not recruiting

Phase 3 study of ianalumab plus standard drug combination in adults and adolescents with systemic lupus erythematosus

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Vila Nova De Gaia

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on head and neck cancer, breast cancer, and multiple myeloma treatments. Studies include evaluations of novel therapies for both early-stage and metastatic conditions.

  • Advanced Head & Neck Squamous Cell Carcinoma
  • HER2-positive Breast Cancer
  • Multiple Myeloma Maintenance Therapy

Research encompasses targeted therapies and combination treatments aimed at improving patient outcomes.

02 Autoimmune Disorders

Comprehensive studies investigating treatments for various autoimmune conditions, including Sjögren's Syndrome and systemic sclerosis. Focus on developing targeted therapies for immune system regulation.

  • Primary Sjögren's Disease
  • Diffuse Cutaneous Systemic Sclerosis
  • Immune Thrombocytopenia

Evaluating novel biological therapies to address complex autoimmune manifestations.

03 Metabolic & Cardiovascular Studies

Research focused on obesity management and cardiovascular health. Studies evaluate new therapeutic approaches for weight management and cardiovascular disease prevention.

  • Obesity Treatment
  • Pulmonary Arterial Hypertension
  • Cardiovascular Risk Management

Investigating innovative treatments to address growing metabolic health challenges.

Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.